Shay Capital’s Exagen XGN Stock Holding History

Shay Capital’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-33,694	Closed	-$205K	–	662
2025 Q4	$205K	Buy	+33,694	New	+$307K	0.02%	412

Other funds holding XGN

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return

Acadian Asset Management

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Shay Capital's XGN Position: Q1 2026 in Review

Shay Capital sold out of Exagen (XGN) in Q1 2026, closing a stake of 33,694 shares — an estimated $205K sold.

Shay Capital first reported a position in XGN in Q4 2025 and held it in 1 quarter. The position peaked at $205K in Q4 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

Shay Capital reported no remaining Exagen position as of Q1 2026 after selling out during the quarter.
Shay Capital sold 33,694 Exagen shares in Q1 2026, an estimated $205K.
Shay Capital first reported a position in Exagen in Q4 2025 and held it in 1 quarter.
Shay Capital's Exagen position peaked at $205K in Q4 2025.
61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Shay Capital's 13F filing for Q1 2026, filed 15 May 2026.